Filing Details

Accession Number:
0001209191-17-053141
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-18 16:02:10
Reporting Period:
2017-09-14
Accepted Time:
2017-09-18 16:02:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131324 Genomic Health Inc GHDX Services-Medical Laboratories (8071) 770552594
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1333482 J Kimberly Popovits 301 Penobscot Dr.
Redwood City CA 94063
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-09-14 5,000 $17.33 46,132 No 4 M Direct
Common Stock Disposition 2017-09-14 5,000 $31.00 41,132 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2017-09-14 5,000 $0.00 0 $17.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
32,900 2018-12-04 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 12,298 Indirect Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits
Common Stock 16,825 Indirect Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee.
Common Stock 237,312 Indirect Held by the Popovits 2010 Trust
Footnotes
  1. Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
  2. Reporting person transferred 37,925 shares from Directly Held to Indirectly Held on August 22, 2017.
  3. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2017.
  4. Represents weighted average sale price. Actual sale prices ranged from $30.77 to $31.27.
  5. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  6. The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.